Legend Biotech/$LEGN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Legend Biotech
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
- Ticker
- $LEGN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,300
- Headquarters
- Somerset, United States
- Website
- legendbiotech.com
Legend Biotech Metrics
BasicAdvanced
$3.6B
-
-$0.01
0.55
-
Price and volume
Market cap
$3.6B
Beta
0.55
52-week high
$37.50
52-week low
$16.24
Average daily volume
2.3M
Financial strength
Current ratio
3.953
Quick ratio
3.7
Long term debt to equity
0.088
Total debt to equity
0.132
Interest coverage (TTM)
2.05%
Profitability
EBITDA (TTM)
50.1
Gross margin (TTM)
56.98%
Net profit margin (TTM)
-0.01%
Operating margin (TTM)
2.75%
Effective tax rate (TTM)
100.62%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
1.37%
Return on equity (TTM)
-0.02%
Valuation
Price to revenue (TTM)
2.561
Price to book
2.83
Price to tangible book (TTM)
2.83
Price to free cash flow (TTM)
-17.114
Free cash flow yield (TTM)
-5.84%
Free cash flow per share (TTM)
-1.083
Growth
Revenue change (TTM)
49.44%
Earnings per share change (TTM)
-99.07%
3-year revenue growth (CAGR)
79.90%
3-year earnings per share growth (CAGR)
-84.00%
What the Analysts think about Legend Biotech
Analyst ratings (Buy, Hold, Sell) for Legend Biotech stock.
Analyst projections of the future price of Legend Biotech stock.
Bulls say / Bears say
CARVYKTI’s commercial momentum is translating into better results: third-quarter net trade sales grew 36% year on year to about $710 million, and Legend reported operating profit of $46.8 million versus a loss a year earlier. (Legend Biotech)
Long-term data suggest CARVYKTI can deliver unusually durable benefit: in a small 20-patient study, half were alive and progression-free without further myeloma treatment five years after one infusion. This could support use earlier in the disease course. (Legend Biotech)
Legend’s in vivo CAR-T programme offers a potential growth avenue beyond its current lead product. In early LB2501 data, all six patients treated at the higher dose responded, though the results are still from a very small study. (Legend Biotech)
CARVYKTI faces growing competition from off-the-shelf bispecific drugs and a prospective rival CAR-T therapy, while bringing treatment to community centres remains difficult. Those pressures could slow adoption even as the market expands. (Fierce Pharma)
CARVYKTI carries material treatment risks: study data report cytokine release syndrome in 84% of patients and neurological toxicities in 24%, while early deaths in one trial were numerically higher in the treatment arm than in the control arm. Such risks may complicate treatment decisions and wider uptake. (Legend Biotech)
Revenue remains concentrated in CARVYKTI: third-quarter collaboration revenue was $353.2 million, driven by the drug’s sales, while license and other revenue was only $6.3 million. A slowdown or setback for the lead product would therefore leave little current revenue diversification. (Legend Biotech)
Data summarised monthly by Lightyear AI. Last updated on 10 Nov 2026.
Legend Biotech Financial Performance
Revenues and expenses
Legend Biotech Earnings Performance
Company profitability
Upcoming events
No upcoming events
Legend Biotech News
AllArticlesVideos
What Legend Biotech (LEGN) Said on Its Q3 Earnings Call
MarketBeat3 days ago
Legend Biotech taps Novartis veteran Zhang as CEO
Reuters2 months ago
Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July
WSJ2 months ago
Funds containing Legend Biotech
Fund name | Fund size | $LEGN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.11% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.11% |
iShares MSCI China€ICGA | $2.4B | 0.06% |
SPDR MSCI EM Asia€SPYA | $1.5B | 0.02% |
SPDR MSCI EM Asia$EMAD | $1.5B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.